(NASDAQ: ALVO) Alvotech's forecast annual revenue growth rate of 22.11% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 279.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.58%.
Alvotech's revenue in 2025 is $573,350,000.On average, 7 Wall Street analysts forecast ALVO's revenue for 2025 to be $185,446,310,792, with the lowest ALVO revenue forecast at $175,677,614,614, and the highest ALVO revenue forecast at $195,000,002,173. On average, 6 Wall Street analysts forecast ALVO's revenue for 2026 to be $265,256,714,366, with the lowest ALVO revenue forecast at $248,648,372,857, and the highest ALVO revenue forecast at $280,394,298,427.
In 2027, ALVO is forecast to generate $348,370,090,172 in revenue, with the lowest revenue forecast at $328,427,616,316 and the highest revenue forecast at $363,638,546,718.